孟鲁司特联合布地奈德治疗过敏性鼻炎的疗效及其对患者tIgE与sIgE的影响

发布时间：2018-02-16 00:37

本文关键词： 孟鲁司特布地奈德过敏性鼻炎 tIgE与sIgE　出处：《标记免疫分析与临床》2016年09期 　论文类型：期刊论文

【摘要】：目的研究孟鲁司特联合布地奈德治疗过敏性鼻炎的临床疗效和对患者tIgE与sIgE的影响。方法选取我院2011年7月到2015年5月间呼吸科及耳鼻喉科收治的160例过敏性鼻炎患者;随机分为观察组80例和对照组80例,观察组给予孟鲁司特联合布地奈德进行治疗,对照组单纯给予布地奈德进行治疗。比较两组患者治疗前后临床症状评分,同事对比两组治疗前后血清总免疫球蛋白E(TIg E)和特异性免疫球蛋白E(SIg E)浓度。结果观察组和对照组治疗前症状评分分别为11.21±3.46分、11.22±3.29分,治疗后观察组和对照组临床症状评分分别为1.96±0.79分、3.96±0.93分。两组间治疗前症状评分差异无统计学意义(P0.05),治疗后均明显下降,而观察组下降更加明显,差异其有统计学意义(t=3.23,P0.05)。观察组和对照组治疗前TIg E、SIg E水平分别为469.25±36.92k U/L、486.32±32.26k U/L、29.96±16.92k U/L、29.42±17.26 k U/L,差异无统计学意义(P0.05);治疗后分别为249.35±27.13KU/L、362.28±35.18k U/L、12.35±7.13k U/L、14.28±6.18k U/L,两组间治疗后差异有统计学意义(P0.05)。结论孟鲁司特联合布地奈德能够明显减轻过敏性鼻炎患者气道炎症反应,同时降低由Ig E介导的I型变态气道反应炎症,降低血清总免疫球蛋白E(TIg E)和特异性免疫球蛋白E(SIg E)浓度,是一种高效的治疗方法,值得在临床中推广使用。
[Abstract]:Objective to study the clinical efficacy of montelukast combined with budesonide in the treatment of allergic rhinitis and its effect on tIgE and sIgE. Methods from July 2011 to May 2015, 160 patients with allergic rhinitis were treated in the department of respiratory and otolaryngology in our hospital. 80 cases were randomly divided into observation group (n = 80) and control group (n = 80). The observation group was treated with montelukast combined with budesonide, while the control group was treated with budesonide. Colleagues compared the serum total immunoglobulin tig (TIg E) and specific immunoglobulin (sig E) concentrations before and after treatment. Results the symptom scores of the observation group and the control group before treatment were 11.21 卤3.46 and 11.22 卤3.29, respectively. The clinical symptom scores of the observation group and the control group were 1.96 卤0.79 and 3.96 卤0.93, respectively. There was no significant difference in the symptom score between the two groups before and after treatment (P 0.05). The difference was statistically significant (P 0.05). Before treatment, the levels of TIg sig E in observation group and control group were 469.25 卤36.92 k U / L 486.32 卤32.26 k U / L 29.96 卤16.92 k UL / L 29.42 卤17.26 k U / L respectively, the difference was not statistically significant (P 0.05); after treatment, it was 249.35 卤27.13 KU / L 362.28 卤35.18 k UL / L 12.35 卤7.13 k U / L 14.28 卤6.18 k U / L, respectively. There was significant difference between the two groups after treatment. Conclusion conclusion there is a significant difference between the two groups after treatment. Montelukast combined with budesonide can significantly reduce airway inflammation in patients with allergic rhinitis. At the same time, it is an effective treatment method to reduce the inflammation of type I abnormal airway reaction mediated by IgE and the concentration of serum total immunoglobulin tig E and specific immunoglobulin Etig E, which is worth popularizing in clinic.
【作者单位】：同济大学医学院;上海市第一人民医院宝山分院检验科;
【分类号】：R765.21

【相似文献】